© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
June 01, 2022
“This is a new standard of care when managing metastatic bladder cancer patients,” says Joaquim Bellmunt, MD, PhD.
May 15, 2022
The benefit with darolutamide was observed, regardless of whether or not patients had prior local therapy.
May 02, 2022
The study specifically examined this precision medicine pathway in the context of frontline treatment selection between nivolumab with or without ipilimumab and a VEGFR tyrosine kinase inhibitor.
February 20, 2022
An analysis of the phase 2 TITAN-RCC trial found multiple immune cell factors associated with high rates of response to nivolumab/ipilimumab in advanced renal cell carcinoma.